

## Calvin Ding

合伙人  
上海

### 履历

As a U.S.-trained attorney who has worked in China for over a decade, Calvin leverages his international background and local expertise to advise clients in navigating their most pressing and challenging regulatory, compliance, internal and government investigations, litigation and dispute resolution matters.

In the investigations space, Calvin has represented companies and their board committees in matters ranging from corruption and conflicts of interest, to trade compliance and cybersecurity incidents. These investigations span industries, and include work for market leaders in the life sciences, technology and telecommunications, chemicals, automotive, diversified industrials and retail sectors.

To help clients avoid problems, Calvin regularly advises on the design and implementation of comprehensive anti-corruption compliance programs, as well as providing guidance on pre-acquisition due diligence, risk assessments, and remediation. Having spent several years working on the day-to-day implementation of an FCPA compliance program in China to address what was then the largest FCPA case brought by the U.S. Government, Calvin has developed a keen understanding and anticipation for the ways the U.S. Government evaluates official corruption issues and the steps a company takes to forestall and address such problems. In addition, Calvin has served as a member of the anti-corruption compliance monitor



电话

+86 21 6122 3808

传真

+86 21 6122 3899

电邮

[calvin.ding@hoganlovells.com](mailto:calvin.ding@hoganlovells.com)

---

### 语言

英语

普通话

---

### 执业领域

调查

政府关系及政策

亚洲

---

### 行业

汽车

多元化的工业

金融机构

生命科学和保健

技术、媒体和电信

---

team for a global medical device company during a 3-year resolution related to a World Bank Group investigation.

## 代理经验

Advising a multinational information services company in investigating and responding to a ransomware attack.

Advising a Chinese telecommunications company in relation to U.S. trade sanctions and the internal investigations stemming from such sanctions.

Conducting multiple investigations in the life sciences industry relating to allegations of improper sales incentives, channel stuffing, fraudulent expenses, off-label use, and drug re-sale.

Conducting due diligence for an international conglomerate involving entities in multiple jurisdictions, and advising on pre and post-closing actions relating to FCPA and Chinese anti-bribery laws.

Implementing an anti-corruption compliance program in China to address one of the largest FCPA investigations brought to date by the U.S. Government.\*

Evaluating an international medical device manufacturer's anti-corruption compliance programs and advising the company and an international financial institution on the adequacy of those programs.\*

Establishing the Greater China anti-corruption compliance function of one of the largest hotel chains in the world with over 150 properties in China, Taiwan, Hong Kong, and Macau.\*

Conducting due diligence for an international conglomerate involving businesses in multiple jurisdictions, and advising on pre and post-closing actions relating to FCPA and Chinese anti-bribery laws.\*

Advising a leading e-commerce company on the implementation of anti-corruption policies and procedures, including the diligence and clearance of

## 重点领域

霍金路伟中国国际业务组

---

## 教育背景及律师执业资格

### 教育

法学博士, 明尼苏达大学法学院,  
2007

康奈尔大学, 2003

---

### 会员资格

American Bar Association

Cornell Alumni Association of  
Shanghai

---

third party intermediaries and business partners.\*

Defending one of the largest Chinese steel makers and achieving an unprecedented victory against allegations before the USITC involving antitrust, trade secret and false designation of origin claims.\*

Acting as compliance monitor to an international medical device manufacturer to advise the company and a multilateral development bank on the contours and adequacy of anti-corruption programs.\*

Representing the audit committee of a listed company in an internal investigation with respect to conflict of interest, breach of fiduciary duty, and FCPA issues arising out of whistleblower claims.\*

Represented the audit committee of a listed company in an internal investigation conducted in response to media reports alleging breach of fiduciary duties and corruption.\*

\*加入霍金路伟前参与的项目

## 奖项及排名

- Life Sciences and Healthcare: Foreign Firms, Key Lawyer, *Legal 500 China*, 2022
- Regulatory / Compliance: Foreign Firms, Recommended Lawyer, *Legal 500 China*, 2022